Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs

Ascendis Pharma (ASND) PT Raised to $205 at Evercore ISI

September 17, 2024 6:32 AM EDT

Evercore ISI analyst Josh Schimmer raised the price target on Ascendis Pharma (NASDAQ: ASND) to $205.00 (from $191.00) while maintaining a Outperform rating.

The analyst comments "Were still refining some estimates via HCP calls. For now, we model $450M peak TransCON CNP sales in achon. For... More

Ascendis Pharma (ASND) PT Raised to $179 at Jefferies

September 16, 2024 4:35 PM EDT

Jefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $179.00 (from $174.00) while maintaining a Buy rating.

The analyst comments "Co reported pivotal data from Navepegritide (TransCon CNP) in children w/ achondroplasia aged 2-11yo, which showed an... More

BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND), PT $175

September 16, 2024 12:07 PM EDT

BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $175.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst comments "ASND could be on its way to a third approved product using its long-acting TransCon technology. Today, it announced positive topline results for... More

Stifel on Ascendis Pharma (ASND): 'A Clear Win Following Recent Commercial Setbacks'

September 16, 2024 10:25 AM EDT

Stifel analyst Alex Thompson reiterated a Buy rating and $200.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst comments "TransCon CNP succeeded in the Ph2/3 ApproaCH study in achondroplasia. On the primary endpoint of annualized growth velocity (AGV) the drug achieved a 1.49cm/yr delta vs. placebo (p... More

BioMarin Pharma (BMRN) Weakness Tied to Data From Ascendis Pharma (ASND)

September 16, 2024 8:38 AM EDT

BioMarin Pharma (NASDAQ: BMRN) Weakness Tied to Data From Ascendis Pharma (NASDAQ: ASND)

Ascendis Pharma A/S (Nasdaq: ASND) today announced topline data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP... More

Ascendis Pharma (ASND) Reports Pivotal ApproaCH Trial of TransCon CNP Achieved Primary Objective

September 16, 2024 7:01 AM EDT

Ascendis Pharma A/S (Nasdaq: ASND) today announced topline data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP (navepegritide), which included 84 children with achondroplasia (ages 2-11 years) randomized 2:1 (TransCon CNP:placebo). TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly and designed to provide sustained release and continuous exposure of active CNP. In the trial, children treated with once-weekly TransCon CNP... More

Citi Reiterates Buy Rating on Ascendis Pharma (ASND)

September 13, 2024 12:59 PM EDT

Citi analyst David Lebowitz reiterated a Buy rating and $178.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst comments "At the European Society for Medical Oncology (ESMO) (9/13-9/17), Ascendis will present data from the platinum-resistant ovarian cancer (PROC) cohort of its Ph1/2... More

Ascendis Pharma (ASND) to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO

September 13, 2024 8:32 AM EDT

Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) treated with TransCon IL-2 / in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 /. First results will be shared in Poster 762P at ESMO 2024, the annual meeting of the European Society of Medical Oncology being held in Barcelona from September 13-17, 2024.

Of the 18 patients (median age 64 years) included in the initial data, 14 were efficacy evaluable patients who had 1 or more post-baseline tumor assessment(s), plus an... More